External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ASRM 2024

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Oct 23 / Roche
Anti-Müllerian hormone to determine polycystic ovarian morphology: a sub-analysis of the APHRODITE study in an Asian population
An exploratory analysis of a cutoff for anti-Müllerian hormone (AMH) to identify PCOM with high sensitivity in Asian and Japanese women with PCOS phenotype A (the only phenotype diagnosed as PCOS in Japan).

Sign up or login to unlock the full suite of MEDICALLY features

Oct 23 / Roche
Polycystic Ovary Syndrome risk algorithm (PriskA): a pilot study
The PCOS risk algorithm (PriskA), a digital tool designed to predict the risk of PCOS, has been developed to improve early detection. The aim of this study was to assess risk stratification of the PriskA digital tool in a real-world setting.
05:45 PM
Duration 90mins Denver, Colorado
Anti-Müllerian hormone to determine polycystic ovarian morphology: a sub-analysis of the APHRODITE study in an Asian population
Joop Laven

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Denver, Colorado
Polycystic Ovary Syndrome risk algorithm (PriskA): a pilot study
Joop Laven

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar